

Retacrit Supply Disruption

Pfizer has announced they expect a supply disruption of Retacrit (epoetin alfa-epbx). This issue is due to COVID-related manufacturing impacts. Supply and out-of-stock issues are expected in May 2022. Supply recovery will likely be around October 2022 but is subject to change.

What Do I Need to Do for Florida Blue Commercial, Medicare Advantage and Truli for Health Members?

Once Retacrit is unavailable, patients need to be switched temporarily to Procrit or Epogen. If your patients have existing authorizations for Retacrit (Q5105 for end-stage renal disease (ESRD) on dialysis, and Q5106 for non-ESRD use) through Magellan Rx Management, Florida Blue or Truli for Health, you do **not** need to request new authorizations for Procrit or Epogen. This also applies to Florida Blue Medicare Advantage patients with existing authorizations through New Century Health or Florida Blue Medicare. There is no need to request new authorizations for Procrit or Epogen.

For patients with active Retacrit authorizations, claims submitted for Procrit or Epogen (J0886 for ESRD on dialysis, and J0885 for non-ESRD use) **during out-of-stock timeframes** will be accepted. Patients should be converted back to Retacrit when supply recovers.

For BlueCard members, please coordinate with the member's Blue Cross and Blue Shield home plan to determine if a new authorization will be required.

HMO coverage is offered by Truli for Health and Florida Blue HMO, affiliates of Florida Blue. Florida Blue offers health insurance. These companies are independent licensees of the Blue Cross and Blue Shield Association.